Megan Majocha, PhD
@meganmajocha.bsky.social did:plc:npimk377dmsrupl7emrwkqar
Scientific Communications Manager @ Susan G. Komen | Breast Cancer Metastasis Researcher | Dog Mom
Bei Bluesky seit
- Follower
- 34
- Folgt
- 62
- Posts
- 1
- Tage in Ranglisten
- 0
Zusammenfassung
Megan Majocha, PhD (@meganmajocha.bsky.social) ist seit 25 Februar 2025 auf Bluesky. Das Konto hat 34 Follower, folgt 62 Konten und hat 1 Posts veröffentlicht.
Ranglisten-Platzierungen
Die besten Tage, an denen Posts dieses Kontos in Debyas Tagesliste kamen.
Dieses Konto war noch in keiner Tagesrangliste.
Zuletzt gelikte Posts
Öffentliche Likes aus dem Bluesky-Netzwerk.
Phase 3 KEYNOTE-522 final results 👀💥 Javier Cortes, MD, PhD presents data from the trial evaluating pembrolizumab + chemo before surgery, followed by adjuvant pembrolizumab vs placebo. #ASCO26 @ascocancer.bsky.social
Post anzeigenCan some people safely avoid chemo in higher-risk early breast cancer? 🤔 OPTIMA phase 3 tests a genomic-guided strategy vs standard of care in HR+/HER2- #breastcancer. Robert Stein, PhD presents first results at #ASCO26 @ascocancer.bsky.social
Post anzeigenNew biomarker insights from NATALEE trial presented by Stephen Chia, MD 📊 Baseline gene expression shows prognostic & predictive impact in HR+/HER2- early #breastcancer treated with adjuvant ribociclib + aromatase inhibitor #ASCO26 @ascocancer.bsky.social
Post anzeigenRecurrence remains a challenge in HR+/HER2- early #breastcancer. Phase 3 lidERA trial previously showed improvement with giredestrant (oral SERD) vs standard hormone therapy 📈 Peter Schmid, MD, PhD presents results by menopausal status at #ASCO26 @ascocancer.bsky.social
Post anzeigen🚀 At #SABCS25, Ben Park, MD, PhD showed how cell signals go "off the rails" in breast cancer and how his groundbreaking work with cfDNA is changing care by helping earlier detection, better treatment tracking, and spotting metastasis sooner. @sabcs.bsky.social
Post anzeigen
Blockierte Konten
Blockierungen sind auf Bluesky öffentlich.
Dieses Konto blockiert niemanden.